Impedimed Ltd has released a press release.
Appendix 4C - Quarter ended 31 December 2019
Filed with ASX ·
Watch Impedimed's latest callImpedimed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of Impedimed (ASX:IPD) Q1 2027 Earnings Call6ix hasn’t read this filing yet.
Earlier from Impedimed
- FDA 510(k) Clearance-Protein Calorie Malnutrition Assessment
- Investor Presentation - Annual General Meeting
- Appendix 4C - Quarter ended 30 September 2019
- Lymphoedema Prevention Program Announced
- Appendix 4E for year ended 30 June 2019
Later from Impedimed
- NCCN Guidelines for Breast Cancer Updated for Lymphoedema
- Appendix 4D and Interim Financial Report (Signed)
- Baylor Scott & White Expands SOZO Use with New iOS Software
- New National Purchasing Agreement for Lymphoedema Prevention
- ImpediMed Secures Order from Large US Oncology Care Network
Follow Impedimed into a list and get an email when it puts out news.
Follow Impedimed